STADA Health Report: 81 percent of Europeans are open towards genetic testing

Preventive health measures are part of everyday life for many Europeans – whether it is a healthy diet, exercise or check-ups at the doctor. With genetic testing, we can now even calculate potential future health risks more accurately and offer more suitable treatment for certain medical conditions. The STADA Health Report 2023 shows that the vast majority of Europeans has a positive attitude towards this idea: 81 percent would agree to genetic testing.

Although 14 percent of this majority would agree, they still feel uncomfortable knowing that their genes are being examined. 19 percent would decide against genetic testing altogether. The major reason: 12 percent do not want to know what risks await them in the future. Surprisingly, there are no major differences in this opinion in different age groups or between the sexes.

Throughout Europe, Portugal (94 percent), Poland (89 percent), Romania and Spain (87 percent each) are the countries with the most positive attitude towards genetic testing. In contrast, Switzerland (70 percent) and the Netherlands (72 percent) emerge as the countries least likely to consider genetic testing.

These are the results of the fifth international STADA Health Report 2023, a representative study with over 32,000 respondents from 16 countries. On behalf of STADA Arzneimittel AG, the market research institute Human8 surveyed around 2,000 people each between the ages of 18 and 99 from: Austria, Belgium, the Czech Republic, France, Germany, Italy, Kazakhstan, the Netherlands, Poland, Portugal, Romania, Serbia, Spain, Switzerland, the United Kingdom and Uzbekistan.

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In the financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18
61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:
STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations